Humana (HUM) Stock Forecast & Price Target

Humana is expected to have a stable trend in April based on recent data, and with an estimated 560 BPS of margin expansion available by CY27-CY28, the company has room to achieve its target margin by CY28. The launch of plan finder and release of CY27 Star Ratings are likely to de-risk the CY27-CY28 turnaround and dominate the narrative in the second half of 2026. Risks include potential MA reimbursement reductions and increasing competition, but these are balanced by the company's solid execution and potential for significant earnings recapture in 2028. Valuation is based on a higher multiple of ~15.5x, reflecting the rise in peer multiples and greater conviction in the company's earnings recovery.

Humana is a Medicare Advantage focused insurance company with a niche in government-sponsored programs, which poses a risk as changes to these programs and government policies could negatively impact the company. The company's current strategy of targeting higher growth potential areas, such as primary-care services and at-home services, may not be enough to offset the potential risks in its government-sponsored programs. Additionally, the company's significant reliance on Medicare and Medicaid membership could result in lower profits due to higher morbidity and mortality rates.